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ABSTRACT
ObjeCtive
To determine whether patient controlled analgesia 
(PCA) is better than routine care in providing effective 
analgesia for patients presenting to emergency 
departments with moderate to severe non-traumatic 
abdominal pain.
Design





200 adults (66% (n=130) female), aged 18 to 75 years, 
who presented to the emergency department requiring 
intravenous opioid analgesia for the treatment of 
moderate to severe non-traumatic abdominal pain and 
were expected to be admitted to hospital for at least 12 
hours.
interventiOns
Patient controlled analgesia or nurse titrated analgesia 
(treatment as usual).
Main OutCOMe Measures
The primary outcome was total pain experienced over 
the 12 hour study period, derived by standardised area 
under the curve (scaled from 0 to 100) of each 
participant’s hourly pain scores, captured using a 
visual analogue scale. Pre-specified secondary 
outcomes included total morphine use, percentage of 
study period in moderate or severe pain, percentage of 
study period asleep, length of hospital stay, and 
satisfaction with pain management.
results
196 participants were included in the primary analyses 
(99 allocated to PCA and 97 to treatment as usual). 
Mean total pain experienced was 35.3 (SD 25.8) in the 
PCA group compared with 47.3 (24.7) in the treatment 
as usual group. The adjusted between group difference 
was 6.3 (95% confidence interval 0.7 to 11.9). 
Participants in the PCA group received significantly 
more morphine (mean 36.1 (SD 22.4) v 23.6 (13.1) mg; 
mean difference 12.3 (95% confidence interval 7.2 to 
17.4) mg), spent less of the study period in moderate or 
severe pain (32.6% v 46.9%; mean difference 14.5% 
(5.6% to 23.5%)), and were more likely to be perfectly 
or very satisfied with the management of their pain 
(83% (73/88) v 66% (57/87); adjusted odds ratio 2.56 
(1.25 to 5.23)) in comparison with participants in the 
treatment as usual group.
COnClusiOns
Significant reductions in pain can be achieved by PCA 
compared with treatment as usual in patients 
presenting to the emergency department with 
non-traumatic abdominal pain.
trial registratiOn
European Clinical Trials Database 
EudraCT2011-000194-31; Current Controlled Trials 
ISRCTN25343280.
Introduction
Pain is defined as “an unpleasant sensory and emo-
tional experience associated with actual or potential 
tissue damage.”1 Pain is the most common reason for 
patients presenting to the emergency department, 
but it is often not treated effectively.2 In a national 
survey of emergency department patients, 64% 
reported they were in pain.3 The Royal College of 
Emergency Medicine recommends that patients in 
severe pain should receive analgesia within 20 min-
utes of arrival in the emergency department, with 
regular reassessment and further action as required.4 
However, effective analgesia is often not achieved, 
and almost half of patients surveyed thought that 
more could be done to treat their pain in the emer-
gency department.3
Routine care for patients in moderate or severe 
pain often involves the administration of intravenous 
 morphine, which is the standard opioid used in most 
WhAT IS AlReAdy knoWn on ThIS TopIC
Pain is common in patients presenting to emergency departments, but it is often 
not treated effectively
Patient controlled analgesia (PCA) has been shown to be more effective than 
standard methods of analgesia delivery in other clinical areas, but very limited 
evidence exists relating to its use in the emergency setting
No previous trials have reported the use of PCA from emergency admission to the 
hospital ward
WhAT ThIS STudy AddS
PCA was more effective than routine care in managing pain in patients presenting to 
the emergency department with non-traumatic abdominal pain
This is the first study to follow up participants from emergency admission to the 
hospital ward; it has therefore given a pragmatic answer to the question of whether 
PCA should be used in these patients
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hospitals and has been shown to be as effective as other 
opioids.5  In UK emergency departments, analgesia for 
patients in severe pain is provided by nurse delivered 
intravenous morphine administered over several min-
utes to achieve pain relief. This technique is safe and 
effective in the short term but places considerable 
demands on nursing time, particularly when repeated 
doses are needed.6
Once a patient is admitted to a hospital ward, severe 
pain may be managed using strong oral opioid analge-
sia or advanced pain management techniques. Best 
practice includes multimodal analgesia using regular 
paracetamol and non-steroidal anti-inflammatory 
drugs in addition to opioids. The decision to admit a 
patient to the ward has been shown to delay the deliv-
ery of effective analgesia in the emergency department, 
suggesting that this group of patients is at particular 
risk of poor pain management.7
One solution may be to allow patients to deliver 
opioid analgesia themselves via a patient controlled 
analgesia (PCA) device. This device consists of a volu-
metric pump, which delivers a set intravenous dose of 
drug when a control button is pressed. The PCA sys-
tem includes anti-siphon and anti-reflux valves to 
minimise the risk of inadvertent drug delivery. The 
pump has a safety “lockout” period when it will not 
deliver a further dose of opioid. A protocol commonly 
used throughout many UK hospitals, in settings other 
than the emergency department, uses a bolus dose of 
1 mg morphine and a lockout period of five minutes 
and is derived from a broad evidence base.8-11 PCA has 
been shown to be more effective in providing pain 
relief compared with standard methods of analgesia 
delivery in areas such as postoperative care, burns, 
and terminal care.12-15 PCA is most effective in main-
taining analgesia once baseline pain relief has been 
established.16
Despite the high prevalence of pain in emergency 
department patients, evidence relating to the use of 
PCA in this setting is very limited. Previous studies in 
this area have provided limited evidence of the short 
term utility of PCA in emergency patients but have not 
considered the management of pain over the subse-
quent hours after hospital admission.17-20 We identified 
no previous or current studies that combine emergency 
department care with ongoing ward care to assess qual-
ity of pain relief beyond four hours, and no detailed 
analysis of the cost effectiveness of PCA in this setting 
has been reported.
Most painful conditions leading to ED attendance 
may be subdivided into abdominal (visceral) and mus-
culoskeletal (somatic) pain. Any effect of PCA, com-
pared with usual care, may differ between visceral and 
somatic pain. Pain from skeletal injury tends to be well 
localised and proportionate to the degree of trauma in 
most patients. In contrast, visceral pain is poorly local-
ised, often does not reflect the severity of pathology, 
and is associated with referred sensations. Strong auto-
nomic and emotional responses to visceral pain often 
occur. These differences reflect the differing neurobiol-
ogy of the two broad types of pain.21 We therefore 
 considered patients with abdominal pain and patients 
with pain from musculoskeletal trauma as two separate 
populations and conceived two separately powered trials.
The aim of the study reported here was to compare 
morphine delivered by PCA with routine care (nurse 
titrated intravenous morphine in the emergency depart-
ment and oral or parenteral morphine on the wards) in 
adult emergency patients who present in moderate or 
severe pain due to non-traumatic abdominal pain and 
are then admitted to an inpatient ward.
Methods
The detailed methodology and study protocol are 
described in a separate protocol paper.22
study design
The study comprised two contemporaneous multi-
centre, open label, randomised trials of PCA versus 
routine care. Patients presenting to the emergency 
department requiring intravenous analgesia and 
admission to hospital, with either traumatic musculo-
skeletal injury or non-traumatic abdominal pain, 
were potentially eligible for inclusion. Key outcome 
measures were collected at baseline and then hourly 
for 12 hours. Although two separate trials were com-
pleted (one of patients presenting with traumatic 
musculoskeletal injuries, the other of patients with 
non-traumatic abdominal pain), both were based on 
the same protocol, which is outlined briefly below. 
Nevertheless, we have considered them as two sepa-
rate trials because they were powered separately. This 
paper reports the trial of patients with non-traumatic 
abdominal pain.
Participants
Eligible patients were adults presenting to the emer-
gency department with non-traumatic abdominal 
pain requiring intravenous opioid analgesia and hos-
pital admission for at least 12 hours from the time of 
enrolment. We excluded patients with chronic pain 
and those with opiate tolerance; a full list of exclu-
sion criteria is available in table 1 of the protocol 
paper.22 Study participants were patients who met the 
eligibility criteria and were willing and able to give 
informed consent.
study recruitment
Patients underwent initial assessment and manage-
ment, including initial pain relief, according to local 
policy. A research nurse screened patients on their 
arrival at the emergency department. After initial 
assessment and pain management, a research nurse 
approached them and gave them an information sheet 
detailing the study. If patients were happy to discuss 
the study further, any questions were answered at this 
stage. Patients were then fully assessed against the 
inclusion and exclusion criteria before written informed 
consent was obtained from those who were willing and 
able to participate. Patients who declined to take part 
were not obliged to give a reason, but the research nurse 
recorded any reasons given.
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study procedures and data collection
After informed consent was obtained, the first study 
pain score was recorded using a visual analogue scale, 
and the participant was randomised (using a secure 
web based randomisation system) to receive either PCA 
or routine care.
Participants in both groups then received instruc-
tions on how to complete subsequent visual analogue 
scale scores, which were entered into a mini flipchart 
(the participant was instructed to turn the page of the 
flipchart after an entry was made, so the previous 
score was not visible for comparison). Participants 
were asked to record their pain scores on deep breath-
ing. Electronic timers (Casio F-91W digital watches) 
issued a bleep every hour as a reminder to the partici-
pant to complete the hourly score, but this bleep was 
not typically loud enough to wake the participant from 
sleep. The visual analogue scale was presented as a 10 
cm horizontal line with verbal anchors at each end of 
“no pain” and “worst pain possible.” Participants 
were instructed to select the point along the line (and 
mark this point with a pen with a single vertical line) 
that reflected their current pain perception. Partici-
pants recorded visual analogue scale pain scores at 60 
minute intervals over a 12 hour period. Participants 
were also instructed on how to record periods asleep, 
retrospectively, on the booklet by using a tick box on 
each page.
Most other outcome data were collected for 12 hours 
from the point at which the first study pain score was 
completed. Opioid use was recorded from the pre-
scribed drugs administered as recorded on the patient’s 
drug chart during the study period (including that pre-
scribed pre-admission). We used study observation 
charts, based on standard hospital charts, for all study 
participants; these were completed as part of routine 
care by emergency department nurses in the emergency 
department and then by ward nurses after inpatient 
ward admission. Observations followed the standard of 
care in each centre. Typically, this involved observa-
tions hourly for four hours, two hourly for eight hours, 
and four hourly thereafter. In practice, this meant 
hourly vital signs in the emergency department and two 
hourly vital signs for the rest of the study period. Obser-
vations included heart rate, blood pressure, respiratory 
rate, oxygen saturations, oxygen flow rate, sedation 
score, and nausea score (0-2). A research nurse reviewed 
the observation charts after the 12 hour study period 
and transcribed out of range results into the study case 
report form.
Where possible, at the end of the 12 hour study period 
(or the following morning as appropriate), a research 
nurse visited participants in both groups to facilitate 
collection of study data. The final page of the data col-
lection booklet included a five point pain management 
satisfaction score ranging from “perfectly satisfied” to 
“not satisfied at all.” Following the participant’s dis-
charge, the research nurse obtained the length of stay 
in hospital and final diagnosis at discharge from the 
patient administration system (or equivalent) and 
recorded them in the case report form.
interventions
Participants allocated to receive routine care were 
prescribed intravenous morphine while in the emer-
gency department and oral morphine (or subcutane-
ous/intramuscular for those nil by mouth) when 
transferred to the hospital ward. Participants ran-
domised to the PCA group received instruction from 
the research nurse in how to operate the PCA device, 
which was set up by the emergency department 
nurses and started with a 1 mg morphine bolus and a 
five minute lockout. PCA was continued for a mini-
mum period of 12 hours; in practice, the clinical team 
reviewed ongoing requirement for PCA the following 
morning. Participants in both groups were prescribed 
multi-modal analgesia in addition, including parac-
etamol and a non-steroidal anti-inflammatory drug 
(unless contraindicated), and were also prescribed 
antiemetics as required.
Primary outcome measure
The primary outcome measure was the total pain expe-
rienced over the 12 hour study period, as captured by 
the hourly completion of a visual analogue pain rating 
scale. We derived this by plotting data as a graph of 
visual analogue scale pain against time and calculating 
the area under the curve for each participant. This is a 
measure of overall pain experienced during the study 
period.23
secondary outcome measures
Secondary outcome measures included total opioid 
dose, out of range vital signs, patients satisfaction with 
pain management, proportion of study period in mod-
erate/severe pain (that is with visual analogue scale 
>4.4 cm), proportion of study period spent sleeping, 
and length of hospital stay.
randomisation, allocation concealment, and 
blinding
Randomisation (one to one) to either PCA or routine 
care was done via a secure web based randomisation 
system. Research team members accessing the rando-
misation website did not know the allocation for an 
individual patient until the relevant details were 
entered and recruitment confirmed.
As pain experience over subsequent hours may be 
affected by the time of day of recruitment (those start-
ing the trial later in the day would be scoring their pain 
during night hours when they may spend a greater pro-
portion of time asleep), randomisation was stratified by 
time of the first recorded pain score (morning or after-
noon/evening), as well as by recruitment centre. 
Blinding was not possible for this study owing to the 
nature of the intervention.
sample size
We derived the primary outcome by plotting data as a 
graph of visual analogue scale pain against time and 
calculating an area under the curve for each partici-
pant. This is a measure of overall pain experienced 
during the study period.23
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Very few studies have considered the question of 
what reduction in area under the curve might be a clin-
ically significant analgesic effect. One study by Camu 
et al showed that a 20% reduction in the area under the 
curve for pain on movement was associated with a 26% 
absolute increase in the proportion of patients report-
ing their global rating of pain relief as very good or 
excellent (P=0.01).24 Conservatively, therefore, we chose 
a difference in area under the curve of 15% between PCA 
and routine care groups as being of clinical signifi-
cance. On a standardised area under the curve (scoring 
between 0 and 100), we expected the routine care group 
to have an average score of about 40 units, so 15% 
equates to a six point reduction. A standard deviation 
can be estimated from the research by Camu et al as 
about 15 units. On the basis of these assumptions, and 
using a two tailed, two sample t test, with a type 1 error 
rate of 0.05, a sample size of 100 patients per group pro-
vides sufficient power (80%) to detect a between group 
difference of 15%.
statistical analyses
We report and present data according to the relevant 
CONSORT statement.25 The primary analyses were all 
pre-specified in a detailed statistical analysis plan 
approved by the Data Monitoring Committee before 
the analyses started. They followed an intention to 
treat approach, with the intent to treat population 
defined as all participants who completed the base-
line and at least one subsequent pain visual ana-
logue scale. Primary analyses were adjusted for the 
stratification factors (centre and time of baseline 
pain score (morning or afternoon/evening)) as fixed 
effects; we also present unadjusted analyses. We 
present 95% confidence intervals for between group 
differences, with the significance level for hypothesis 
testing set at 5%.
We used the area under the curve approach to cap-
ture the primary outcome measure of total pain expe-
rienced and compared it between PCA and routine 
care groups by using analysis of covariance, including 
the two stratification variables and the baseline pain 
score as covariates. We did this analysis blinded to the 
allocated group. We calculated the area under the 
curve by using the “trapezoidal” rule, using straight 
lines to join visual analogue scale scores and calculat-
ing the area under them for the 12 hour period. In gen-
eral, where one or more hourly pain scores were not 
recorded, we imputed values by linear interpolation if 
scores were recorded either side and by last observa-
tion carried forward if scores were missing at the end 
of the 12 hour period, except that such final scores 
were recorded as zero if the participant was discharged 
(or self discharged). These conventions were agreed 
with the Trial Steering Committee and Data Monitor-
ing Committee in a detailed strategy; a member of the 
Trial Management Group, blinded to participants’ 
allocated group wherever possible, categorised rea-
sons for missing data.
We similarly compared continuous secondary out-
comes between the two groups by using analysis of 
covariance, with adjustment for the two stratification 
variables. Given that some visual suggestion of poten-
tial violations of the linear model assumptions existed, 
we also produced bootstrapped confidence intervals for 
the between group differences for each outcome mea-
sure. In each instance, little difference existed between 
the normal based and bootstrapped confidence inter-
vals; for simplicity, we present only the normal based 
confidence intervals.
For the analysis of participants’ satisfaction with 
pain management, we recoded the five point scale 
(ranging from “perfectly satisfied” to “not at all satis-
fied”) into two categories, combining “perfectly satis-
fied” and “very satisfied” into one category and the 
others into a second category. We used binary logistic 
regression to determine the odds ratio and 95% confi-
dence interval for the group effect, with adjustment for 
the stratification variables.
sensitivity analyses
We did two pre-specified sensitivity analyses of the pri-
mary outcome measure: the first scored pain as zero for 
periods of sleep (sensitivity 1); the second imputed 
missing pain scores due to transfers to theatre by using 
linear interpolation from the last recorded pain score to 
zero at the 12 hour time point (sensitivity 2).
At the request of the Data Monitoring Committee, we 
also did two further sensitivity analyses. The first of 
these included the data from the four participants in 
the hospital that was excluded in the primary analyses 
(see below; sensitivity 3). The second excluded 35 par-
ticipants whose baseline pain score seemed to be 
recorded after randomisation. Data validation checks 
showed this possibility for some patients, although 
verification was not straightforward as different 
sources were used to record the times of baseline pain 
score and randomisation. We considered that if the 
baseline pain score had a recorded time of more than 
five minutes after the recorded time of randomisation, 
this probably indicated that the score was recorded 
after randomisation; these are the 35 cases that were 
excluded in sensitivity 4.
Patient involvement
During the design of this study, a patient representative 
contributed to the development of the grant application 
and, later, to the study protocol and participant facing 
documentation after funding had been awarded. We 
also had a patient representative on the Trial Steering 
Committee, who helped to oversee progress of the trial 
and provided a patient’s perspective on aspects of trial 
conduct. A lay summary of the study findings will be 




The figure outlines the flow of participants in the trial. 
Recruitment took place from July 2011 to May 2013. Of 
363 eligible patients who were approached to partici-
pate, 104 (28%) declined and a further 50 (14%) did not 
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participate for other reasons. The remaining 209 
patients consented and were randomised: 104 to PCA 
and 105 to treatment as usual. Three participants in the 
PCA group and six participants in the TAU group were 
not included in the statistical analyses, owing either to 
the booklets with the pain scores going missing or to the 
participant completing the pain score only once. One 
participating hospital experienced some local difficul-
ties in implementing the protocol as intended, and only 
four patients were recruited at this site, making the 
pre-specified adjustment for centre impossible. On the 
advice of the Data Monitoring Committee, we excluded 
data from this site from the primary analyses. This left a 
total of 196 participants, 99 randomised to PCA and 97 
randomised to treatment as usual, for the primary sta-
tistical analyses.
baseline characteristics
Participants were aged 18 to 75 years, and two thirds 
were women (table 1). At the time of emergency depart-
ment admission, participants’ mean verbal rated pain 
score was 8.0 (range 0-10). The median time from arrival 
in the ED to randomisation was 152 (29-768) minutes. By 
the time participants completed their first study pain 
score, the median overall visual analogue pain score 
was 5.2 (0-10). The two randomised groups were similar 
in terms of most characteristics, with a slight difference 
in median baseline visual analogue scale pain scores: 
4.8 (0-9.8) in the PCA group and 6.1 (0-10) in the treat-
ment as usual group.
Primary outcome (including sensitivity analyses)
Mean total pain experienced in the PCA group was 35.3 
(SD 25.8) compared with 47.3 (24.7) in the treatment as 
usual group (table 2). The primary analysis, with 
adjustment for centre, time of baseline pain score, and 
baseline pain score, showed a statistically significant 
between group difference of 6.3 (95% confidence inter-
val 0.7 to 11.9) units. In both pre-specified sensitivity 
analyses, the between group difference remained sta-
tistically significant. Including the data from the fifth 
hospital slightly increased the magnitude of the 
adjusted between group difference, whereas excluding 
the data from the 35 participants with more than five 
minutes between time of baseline pain score and time 
of randomisation did not change the magnitude of the 
between group difference, although the difference was 
no longer statistically  significant at the 5% level.
secondary outcomes
Participants in the PCA group used significantly more 
morphine on average compared with the treatment as 
usual group, in terms of total morphine (morphine given 
pre-admission, from time of admission to time of recruit-
ment, and during the study period) (adjusted mean 
increase of 12.3 (95% confidence interval 7.2 to 17.4) mg) 
and morphine used during the 12 hour study period 
(adjusted mean increase of 12.8 (8.3 to 17.2) mg) (table 3).
A higher proportion of the PCA group than the treat-
ment as usual group had at least one out of range vital 
sign (64/99 (65%) v 38/97 (39%)). In particular, a signifi-
cantly greater proportion of participants in the PCA 
group had one or more episodes of nausea compared 
with the treatment as usual group (adjusted odds ratio 
4.99, 95% confidence interval 2.45 to 10.15). One partici-
pant in the treatment as usual group also had one 
instance of hypoxia.
On average, participants in the PCA group spent 
less of the study period in moderate or severe pain 
compared with participants in the treatment as usual 
group (mean difference of 14.5%, 5.6% to 23.5%). 
Adjusting for the baseline pain score reduced the 
mean difference to 7.3% (0.3% to 14.4%), but the dif-
ference remained statistically significant. We found 
no evidence of differences between the groups in 
terms of percentage of the study period spent asleep 
or the length of hospital stay.
Participants allocated to the PCA group were signifi-
cantly more likely to report being perfectly or very satis-
fied with the management of their pain compared with 
participants in the treatment as usual group (73/88 (83%) 
v 57/87 (66%); adjusted odds ratio 2.56, 1.25 to 5.23).
PCA (n=104)Treatment as usual (n=105)






Received treatment as usual (n=105*)
Data from site 5 removed
from analyses† (n=2)
Analysed (n=97)
Data from site 5 removed
from analyses† (n=2)
Excluded (n=3):
  VAS booklet lost (n=3)
Data available (n=99)
Excluded (n=6):
  VAS booklet lost (n=3)
  Insucient VAS data (n=3)
Declined to consent (n=104):
  No reason provided (n=53)
  Not interested (n=28)
  In too much pain (n=6)
  Did not want to stay in hospital (n=4)
  Too anxious or distressed (n=3)
  Did not feel well enough (n=3)
  Dislike eect of morphine (n=2)
  Declined further analgesia (n=1)
  Pain relieved aer initial dose (n=1)
  Too tired (n=1)
  Concerned about medical cover (n=1)
  Complex medical history (n=1)
Did not take part for other reasons (n=50):
  No authorised clinicians available (n=32)
  No further information (n=10)
  No GCP trained sta to consent (n=8)
Flow of participants through study. gCP=good clinical practice; PCa=patient controlled 
analgesia; vas=visual analogue scale. *4 participants transferred between treatment 
groups during 12 hour study period: all 4 patients discontinued PCa and went into 
treatment as usual. †Following advice from the Data Monitoring Committee’s independent 
statistician, participants recruited at site 5 were excluded
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adverse events
Six non-serious adverse effects were reported. All were 
mild; all were related to morphine and were expected: 
four were itching, one was a rash, and one was urticaria 
at the cannulation site.
discussion
This study found that PCA provided more effective anal-
gesia than routine care in emergency patients admitted 
to hospital with abdominal pain. We found a modest 
reduction in overall pain scores, as well as a significant 
table 2 | Primary outcome of total pain experienced (standardised area under curve, maximum score 100): primary and sensitivity analyses
analysis
Mean (sD; range) adjusted analysis* unadjusted analysis
treatment as usual  
(n=97)




Mean difference†  
(95% Ci) P value
Primary 47.3 (24.7; 1.0-99.5) 35.3 (25.8; 1.5-94.8) 6.3 (0.7 to 11.9) 0.027 11.9 (4.8 to 19.0) 0.001
Sensitivity 1‡ 37.7 (21.5; 0.7-96.3) 28.2 (22.3; 1.5-83.6) 5.2 (0.1 to 10.2) 0.047 9.6 (3.4 to 15.7) 0.003
Sensitivity 2§ 46.7 (24.7; 0.9-99.5) 34.7 (25.5; 1.5-94.8) 6.5 (0.9 to 12.0) 0.022 12.0 (4.9 to 19.1) 0.001
Sensitivity3¶ 47.7 (24.6; 1.0-99.5) (n=99) 35.2 (25.6; 1.5-94.8) (n=101) 7.2 (1.6 to 12.8) 0.012 12.5 (5.5 to 19.5) 0.001
Sensitivity 4** 49.2 (23.3; 1.0-99.5) (n=79) 36.7 (25.7; 1.5-94.8) (n=82) 6.3 (−0.2 to 12.7) 0.056 12.5 (4.8 to 20.1) 0.002
*Adjusted for stratification variables (time of first pain score and recruitment centre) and baseline pain score.
†Treatment as usual minus patient controlled analgesia.
‡Pain scored as zero for periods of sleep.
§Missing pain scores for theatre withdrawals imputed using linear interpolation from last recorded pain score to zero at 12 hour time point.
¶Includes data from four participants in centre 5.
**Excludes data from 35 participants with >5 minutes between time of first pain score and time of randomisation.
table 1 | baseline and demographic data. values are percentages (numbers) unless stated otherwise
treatment as usual  
(n=97)





Female sex 66 (64) 67 (66) 66 (130)
Mean (SD; range) age, years 41.3 (15.3; 18-75) 41.5 (15.4; 18-72) 41.4 (15.3; 18-75)
Median (IQR; range) verbal rated pain score (0-10, 
as recorded on hospital administration system)
8 (6-9; 0-10) (n=93) 8 (6-9; 0-10) (n=95) 8 (6-9; 0-10) (n=188)
Median (IQR; range) visual analogue pain score  
(at time of consent), cm
6.1 (3.2-7.7; 0-10) 4.8 (2.2-6.8; 0-9.8) 5.2 (2.5-7.3; 0-10)
time of recruitment
Morning (0600-1159) 36 (35) 38 (38) 37 (73)
Afternoon (1200-2200) 64 (62) 62 (61) 63 (123)
Mean (SD; range) time from arrival in emergency 
department to randomisation, minutes
162.4 (83.9; 29-586) 164.7 (83.4; 54-768) 163.6 (83.5; 29-768)
recruitment centre
Centre 1 63 (61) 67 (66) 65 (127)
Centre 2 16 (16) 15 (15) 16 (31)
Centre 3 11 (11) 11 (11) 11 (22)
Centre 4 9 (9) 7 (7) 8 (16)
Clinical diagnosis
Bowel pathology (including obstruction, 
diverticular disease, hernia with obstruction)
14 (14) 16 (16) 15 (30)
Gall bladder pathology (including biliary system) 15 (15) 13 (13) 14 (28)
Renal or ureteric pathology (stone passed) 14.4 (14) 14 (14) 14 (28)
Pancreatic pathology 8 (8) 9 (9) 9 (17)
Appendix pathology 7 (7) 6 (6) 7 (13)
Renal or ureteric pathology 8 (8) 4 (4) 6 (12)
Gynaecological pathology (including ovarian) 7 (7) 4 (4) 6 (11)
Oesophagitis or gastritis 4 (4) 4 (4) 4 (8)
Abdominal pain (not further specified) 14 (14) 20 (20) 17 (34)
Other  (including postoperative pain, hepatic  
neoplasm)
6 (6) 9 (9) 8 (15)
Preadmission analgesia
Mean (SD; range) morphine (mg): 
 Participants with pre-admission morphine 9.1 (6.1; 1.7-30.0) (n=35) 8.9 (4.2; 2.5-20.0) (n=33) 9.0 (5.2; 1.7-30.0) (n=68)
 All participants 3.3 (5.7; 0-30) 3.0 (4.8; 0-20) 3.1 (5.3; (0-30)
At least one dose in 24 hours before emergency 
department arrival:
 Analgesic gas 3 (3) 7 (7) 5 (10)
 Non-steroidal anti-inflammatory drug 15 (15) 9 (9) 12 (24)
 Paracetamol 34 (33) 32 (32) 33 (65)
 Weak opioid 14 (14) 9 (9) 12 (23)
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reduction in the amount of time that participants spent 
in moderate and severe pain. Participants in the PCA 
group used significantly more morphine, which may 
reflect under-treatment in the routine care group. Satis-
faction with pain management showed a marked differ-
ence, with a significantly higher satisfaction in the PCA 
group. Patients in the PCA group were more than twice 
as likely to be very or perfectly satisfied with their pain 
management, suggesting that patients may value a 
degree of autonomy in the ability to control their pain.
strengths and limitations of study
The main strength of this study was that it combined 
care in the emergency department with ongoing care 
once the patient was admitted to a hospital ward. It 
investigated the effects of PCA started in the emergency 
department but also subsequently beyond the patient’s 
emergency department stay. This is the first study to 
look at this vulnerable period between emergency care 
and inpatient management.
The lack of blinding in this study could be viewed as a 
limitation, but blinding patients or clinicians to the treat-
ment allocation was not practical. Despite the strict ran-
domisation with concealed allocation, the two groups 
were not perfectly balanced on baseline pain scores. 
However, baseline pain score was included as a covariate 
in the primary analysis and adjusting for baseline pain 
score did not alter the findings for the secondary out-
comes. During data validation, it became apparent that 
the baseline pain score may have been recorded after the 
time of randomisation in several cases, despite the study 
protocol clearly indicating that the first study pain score 
was to be recorded at the time of consent and before ran-
domisation. However, further analyses showed no evi-
dence to suggest that the presumed timing of the baseline 
pain score (that is, before or after the time of randomisa-
tion) accounted for the difference in mean baseline pain 
scores between allocated groups.
Comparisons with other studies and implications of 
this study
Few previous studies have attempted to investigate 
PCA in emergency patients, and none has looked 
beyond the emergency department phase of care. Only 
one study has previously investigated patients with 
abdominal pain. This North American study randomised 
211 emergency patients with abdominal pain to one of 
three groups; standard care, PCA standard dose (1 mg) 
bolus, or PCA higher dose (1.5 mg) bolus.18 It found a 
significant reduction in pain in both PCA groups com-
pared with standard care, but the trial collected data 
during the patients’ emergency department stay only 
and did not continue to follow them after admission to 
a hospital ward.
Although this study has shown clear benefits in the 
use of PCA in this group of patients, we emphasise 
that the routine care arm of this study may not repre-
sent real world emergency care. All patients who were 
allocated to the routine care group were treated with 
multimodal analgesia according to the hospital’s 
guideline, but in many cases and for a variety of rea-
sons this may not always occur in normal practice. 
There may also have been a Hawthorne effect on the 
nurses who were looking after the patients in the rou-
tine care group, and their behaviour may have been 
influenced by this.
Conclusions
This study has shown that PCA is more effective than 
routine care in managing pain in the emergency 
department and during the following hours of hospi-
tal admission in patients with non-traumatic abdom-
inal pain. This is the first study to follow-up 
participants from emergency admission to the hospi-
tal ward; it has therefore given a pragmatic answer 
to the question of whether PCA should be used in 
these patients.
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table 3 | secondary outcomes
Outcome
Mean (sD; range) adjusted analysis* unadjusted analysis
tau (n=97) PCa (n=99)
Mean difference†  
(95% Ci) P value
Mean difference†  
(95% Ci) P value
Total morphine (mg)‡ 23.6 (13.1; (3.0-60.0) 36.1 (22.4; 8.0-106.3) −12.3 (−17.4 to −7.2) <0.001 −12.6 (−17.8 to −7.4) <0.001
Total morphine during 12 hour 
study period (mg)
10.7 (9.6; (0-40.0) 23.6 (20.3; 0 to 96.3) −12.8 (−17.2 to −8.3) <0.001 −12.9 (−17.4 to −8.4) <0.001
Percentage of study period 
with pain VAS >4.4 cm
46.9 (30.5; 0-100) 32.6 (32.5; 0-100) 14.5 (5.6 to 23.5) 0.002 14.3 (5.4 to 23.1) 0.002
Percentage of study period 
asleep
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PCA=patient controlled analgesia; TAU=treatment as usual; VAS=visual analogue scale.
*Adjusted for stratification variables (time of first pain score and recruitment centre).
†TAU minus PCA.
‡Sum of pre-admission morphine, morphine from time of admission to time of recruitment, and morphine delivered during 12 hour study period.
§One outlier excluded from TAU group (length of hospital stay of 88 days).
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